Overview

Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

Demethylating agent decitabine enhances the immunogenicity of leukemia cells by inducing the expression of cancer testis antigens (CTAs),MHC class I and II molecules,costimulatory molecules and adhesion molecules. The leukemias cells treated by decitabine will become more sensitive to the following adoptive T cell therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Chinese PLA General Hospital

Collaborator:

Navy General Hospital, Beijing

Treatments:

Aclacinomycins
Azacitidine
Cytarabine
Decitabine
Lenograstim
Sargramostim